Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Steatohepatitis
Adam Sheka, Oyedele Adeyi, Julie Thompson, et al.
JAMA (2020) Vol. 323, Iss. 12, pp. 1175-1175
Closed Access | Times Cited: 1093

Showing 1-25 of 1093 citing articles:

The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Leon A. Adams, James Lymp, Jenny St. Sauver, et al.
Gastroenterology (2005) Vol. 129, Iss. 1, pp. 113-121
Open Access | Times Cited: 2796
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 12, pp. 1113-1124
Open Access | Times Cited: 1299
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Arun J. Sanyal, Mark L. Van Natta, Jeanne M. Clark, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1559-1569
Open Access | Times Cited: 702
Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
Sarah Hampl, Sandra G. Hassink, Asheley Cockrell Skinner, et al.
PEDIATRICS (2023) Vol. 151, Iss. 2
Closed Access | Times Cited: 642
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 478
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 368
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 334
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 313
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 291
Hesperetin ameliorates hepatic oxidative stress and inflammationviathe PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD
Jingda Li, Tianqi Wang, Panpan Liu, et al.
Food & Function (2021) Vol. 12, Iss. 9, pp. 3898-3918
Closed Access | Times Cited: 273
Lipid droplet biogenesis and functions in health and disease
Armella Zadoorian, Ximing Du, Hongyuan Yang
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 8, pp. 443-459
Open Access | Times Cited: 244
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
Ali Aminian, Abbas Al‐Kurd, Rickesha Wilson, et al.
JAMA (2021) Vol. 326, Iss. 20, pp. 2031-2031
Open Access | Times Cited: 238
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Guy Neff, Cynthia D. Guy, et al.
Gastroenterology (2020) Vol. 160, Iss. 1, pp. 219-231.e1
Open Access | Times Cited: 227
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 11, pp. 951-963
Open Access | Times Cited: 200
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 193
An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD
Grace En Hui Lim, Ansel Shao Pin Tang, Cheng Han Ng, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 21, Iss. 3, pp. 619-629.e7
Open Access | Times Cited: 181
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study
Jiarong Xie, Hangkai Huang, Zhening Liu, et al.
Hepatology (2022) Vol. 77, Iss. 3, pp. 949-964
Open Access | Times Cited: 158
Metabolic drivers of non-alcoholic fatty liver disease
Kendra K. Bence, Morris J. Birnbaum
Molecular Metabolism (2020) Vol. 50, pp. 101143-101143
Open Access | Times Cited: 154
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Oren K. Fix, Emily A. Blumberg, Kyong‐Mi Chang, et al.
Hepatology (2021) Vol. 74, Iss. 2, pp. 1049-1064
Open Access | Times Cited: 151
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1475-1486
Open Access | Times Cited: 149
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas, Arturo Santos, Juan Armendáriz‐Borunda
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11629-11629
Open Access | Times Cited: 145
Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development
Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella
Nutrients (2021) Vol. 13, Iss. 5, pp. 1442-1442
Open Access | Times Cited: 138
Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018)
Wen Gu, Hannah Hortlik, Hans‐Peter Erasmus, et al.
The Lancet Regional Health - Europe (2021) Vol. 12, pp. 100240-100240
Open Access | Times Cited: 123
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Hepatology Research (2021) Vol. 51, Iss. 10, pp. 1013-1025
Open Access | Times Cited: 113
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
Tian Lan, Yu Yang, Jing Zhang, et al.
Hepatology (2021) Vol. 74, Iss. 2, pp. 686-703
Open Access | Times Cited: 111
Page 1 - Next Page

Scroll to top